the probiotic Escherichia coli (E. coli), Nissle 1917, to secrete proteins of therapeutic value into its surroundings. When engineered to secrete an antibody that blocks inflammation, this
Escherichia coli is one of the earliest probiotic bacterial strains to be developed for human therapeutic use (Nissle A, 1916). Among probiotic E. coli strains, E. coli Nissle (EcN) 1917 has been the topic of numerous studies in humans since its discovery in the early 1900s, and is marketed in Germany and other countries under the brand name
To this end, we chose Escherichia coli Nissle 1917 , a probiotic strain that is used commercially as a probiotic and is closely related to model strains of E. coli that are well characterized for
Genetically engineered microbes, especially Escherichia coli, have been widely used in the biosynthesis of proteins and metabolites for medical and industrial applications. As a traditional probiotic with a well-established safety record, E. coli Nissle 1917 (EcN) has recently emerged as a microbial …
The parent strain chosen for development of our BG delivery system is the probiotic Escherichia coli strain Nissle 1917 (EcN), whose intrinsic properties trigger the innate immune system with the flagella and fimbriae used to attach and stimulate epithelial cells. In previous studies, we have shown that EcN BGs are safe for the ocular surface
The aim of the current study was therefore to investigate the antimicrobial and antibiofilm activities of a range of bacteria including organisms isolated from human skin, and the candidate probiotic E. coli Nissle 1917. E. coli Nissle 1917 is a commonly studied candidate probiotic bacterium. e0OR.
